Analyst Ratings for [MGNX] MacroGenics, Inc.

11/7/24	Downgrades	Mkt Outperform Mkt Perform	X
MGNX MacroGenics JMP Securities
8/1/24	Downgrades	Buy Neutral	X
MGNX MacroGenics BTIG Research
7/31/24	Downgrades	Buy Neutral	X
MGNX MacroGenics B. Riley Securities
$18 $5
7/31/24	Downgrades	Buy Neutral	X
MGNX MacroGenics Guggenheim
5/10/24	Downgrades	Outperform Mkt Perform	X
MGNX MacroGenics BMO Capital Markets
$24 $8
5/10/24	Downgrades	Buy Hold	X
MGNX MacroGenics Stifel
$29 $7
5/10/24	Downgrades	Buy Hold	X
MGNX MacroGenics TD Cowen
4/26/24	Initiated	Buy	X
MGNX MacroGenics B. Riley Securities
$25
4/9/24	Upgrades	Hold Buy	X
MGNX MacroGenics TD Cowen
3/4/24	Reiterated	Buy	X
MGNX MacroGenics BTIG Research
$12 $24
2/14/24	Downgrades	Buy Neutral	X
MGNX MacroGenics H.C. Wainwright
$12 $14
11/7/23	Upgrades	Neutral Buy	X
MGNX MacroGenics Guggenheim
$12
3/17/23	Downgrades	Buy Neutral	X
MGNX MacroGenics Guggenheim
11/22/22	Downgrades	Outperform Mkt Perform	X
MGNX MacroGenics Cowen
11/14/22	Upgrades	Mkt Perform Outperform	X
MGNX MacroGenics BMO Capital Markets
$5.70 $16
7/18/22	Downgrades	Outperform Neutral	X
MGNX MacroGenics SMBC Nikko
$5
7/11/22	Downgrades	Outperform Mkt Perform	X
MGNX MacroGenics BMO Capital Markets
$31 $4
5/4/22	Downgrades	Buy Neutral	X
MGNX MacroGenics Guggenheim
2/11/22	Initiated	Outperform	X
MGNX MacroGenics BMO Capital Markets
$31
2/4/22	Initiated	Outperform	X
MGNX MacroGenics SMBC Nikko
$40
11/17/21	Resumed	Buy	X
MGNX MacroGenics Guggenheim
$30
10/19/21	Initiated	Mkt Outperform	X
MGNX MacroGenics JMP Securities
$39
10/15/21	Resumed	Buy	X
MGNX MacroGenics BTIG Research
$50
4/26/21	Resumed	Outperform	X
MGNX MacroGenics Credit Suisse
$37
3/12/21	Upgrades	Underweight Overweight	X
MGNX MacroGenics Barclays
$14 $40
12/22/20	Resumed	Buy	X
MGNX MacroGenics H.C. Wainwright
$36
5/3/19	Upgrades	Neutral Outperform	X
MGNX MacroGenics Wedbush
$26
4/12/19	Initiated	Neutral	X
MGNX MacroGenics Guggenheim
2/7/19	Upgrades	Sell Buy	X
MGNX MacroGenics Citigroup
2/7/19	Downgrades	Outperform Neutral	X
MGNX MacroGenics Wedbush
2/4/19	Downgrades	Neutral Sell	X
MGNX MacroGenics Citigroup
$10
12/10/18	Downgrades	Outperform Underperform	X
MGNX MacroGenics Raymond James
9/10/18	Resumed	Buy	X
MGNX MacroGenics BTIG Research
$30
5/31/18	Initiated	Outperform	X
MGNX MacroGenics Evercore ISI
$33
3/5/18	Initiated	Buy	X
MGNX MacroGenics H.C. Wainwright
$38

MGNX MacroGenics, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.